Skip to content
orbyd

Dossier · TLRY · Dormant

TLRY · Tilray Brands, Inc.

LOW Earnings inflection Catalyst · cannabis-reclassification cannabis-rescheduling-schedule-iii hemp-thc-recriminalization

Last analysed ·

Current thesis

Cannabis Schedule-III reform trade live into the 2026-06-29 DEA adult-use rescheduling hearing (concludes ≤07-15); sector firming (CGC adult-use +43%) and a Congressional hemp-THC ban would clear gray-market competitors but TLRY's chart is busted at ~$5.45, below the 200-day, near 52-week lows. Defined-risk binary probe, not a momentum entry.

Invalidation trigger

Daily close below $4.50 (loss of the pre-hearing base); OR the 2026-06-29→07-15 DEA hearing concludes with no adult-use Schedule III recommendation / a punt to litigation (sell-the-news). No momentum entry until a daily close back above ~$5.80–6.00 reclaims structure.

Thesis status

Open commitment catalyst in 15dscored if the trigger above fires How this is scored →

Current Thesis

The cannabis Schedule-III reform trade is live again into the DEA's expedited adult-use rescheduling hearing (begins 2026-06-29 9am ET, Arlington VA; concludes no later than 2026-07-15). The sector is firming Canopy's Q1 FY2026 adult-use sales rose 43% and a Congressional hemp-derived-THC ban now threatens to clear the gray-market competitors that have undercut licensed cannabis. But TLRY's own tape is broken: ~$5.45 (2026-06-05), below the 200-day SMA, in the bottom tenth of a $3.51–$23.20 52-week range after a full round-trip of the late-2025/April-2026 reform spike. This is a defined-risk bet that the hearing re-ignites the complex, not a trend entry.

Bull Case

  • DEA expedited hearing on BROADER (adult-use) Schedule III rescheduling begins 2026-06-29 9am ET, the first hard federal date in years that could legalize the economics of the state-licensed recreational market currently still Schedule I. (Federal Register, 2026-04-28; DEA notice)
  • Partial rescheduling already executed 2026-04-23: Acting AG Blanche moved FDA-approved drugs + state-licensed medical marijuana to Schedule III, proof the administration acts and not just signals. (DOJ OPA, 2026-04-23)
  • Peer demand is accelerating: Canopy Growth Q1 FY2026 cannabis revenue +24% YoY, Canadian adult-use +43% to $27M, medical +13% the demand side is real ahead of the 2026-06-15 CGC FY2026 print. (Canopy Q1 release, 2025-08-08)
  • New structural tailwind: Congress recriminalized intoxicating hemp-derived THC in the shutdown-ending spending bill (0.4mg total-THC/container cap), set to take effect ~2026-11-12; the U.S. Hemp Roundtable estimates it wipes ~95% of existing hemp-cannabinoid products removing gray-market competition that bled licensed dispensaries. (Akerman LLP; Marijuana Moment, 2026-06-05)
  • Tilray-specific: Q3 FY2026 (reported ~2026-04-01) was a record net revenue $206.7M (+11% YoY), gross profit $55M (+6%), surprise adjusted profit +$0.02/sh; international cannabis +70% YoY on Germany legalization. (Q3 FY2026 call)
  • BrewDog acquisition pushes annualized revenue to ~$1.2B, a diversified beverage + cannabis platform rather than a cash-burning LP. (Q3 FY2026)

Bear Case

  • The chart is a value trap: below the 200-day SMA, near the 52-week low of $3.51, ChartMill technical rating 0/10 with sell signals on both timeframes (2026-06). Momentum books do not initiate below the 200-day into a downtrend.
  • "Rescheduling will finally happen" is the most-burned cannabis trade since 2022; TLRY ran $5→$23→$5, leaving overhead supply at every level and a reform-long base underwater.
  • The 2026-04-23 partial rescheduling was sold hard; the 2026-06-29 hearing carries identical buy-the-rumor/sell-the-fact risk and only CONCLUDES (≤2026-07-15) with a recommendation not a final rule, and litigable from there. (Foley & Lardner, 2026-04)
  • Recreational cannabis explicitly REMAINS Schedule I unless the broader hearing changes it; a "no adult-use" outcome or punt to litigation guts the TLRY-specific catalyst.
  • Still GAAP loss-making: FY2026 EPS consensus near -$0.61 on ~$867M revenue; the "surprise profit" was adjusted, not GAAP. The Street rates it Hold, average 12-month PT $7.98 (6 analysts, 2026-06).
  • Reform beta is diluted: post-BrewDog, cannabis is only ~31% of revenue, so the catalyst now moves a shrinking slice while the rest tracks craft-beer fundamentals.
  • Peer-sentiment risk: CGC files FY2026 on 2026-06-15 alongside a restatement of FY2024 and FY2025 financials (non-cash warrant misclassification) a messy peer print two weeks before the hearing could chill the whole complex. (Motley Fool, 2026-05-22)

Setup & Price Structure

  • Last ~$5.45 (2026-06-05); 2026-06-05 intraday range $5.15–$5.59; ~$5.12 on 2026-06-03.
  • 52-week range $3.51–$23.20 sitting in roughly the bottom 10% after a complete round-trip of the reform spike.
  • Below the 200-day SMA; short- and long-term trend both negative (ChartMill 0/10, 2026-06). No clean higher-low sequence; the structure is basing/busted, not trending.
  • Analyst average PT $7.98 implies ~+54% from $5.45, but the consensus rating is Hold the upside is catalyst-contingent, not a chase setup.
  • Momentum entry requires a daily close back above ~$5.80–$6.00 to reclaim structure; below that this is a binary probe only.

Catalyst Calendar (next 30 days)

  • 2026-06-15 Canopy Growth (CGC) FY2026 results + restatement of FY2024/FY2025; first sector read-through into the hearing.
  • 2026-06-29 09:00 ET DEA expedited adult-use Schedule III rescheduling hearing begins (Arlington, VA). The binary.
  • 2026-07-03 hearing recess.
  • 2026-07-06 hearing reconvenes.
  • ~2026-07-15 (just past 30d) hearing concludes; recommendation expected (not a final rule).
  • Backdrop, no fixed in-window date ongoing House/Senate fight to amend the hemp-THC ban before its ~2026-11-12 effective date (H.R. 7024 would defer to 2028); White House pushing Congress to preserve full-spectrum CBD (2026-06-05).

What Would Change Our Mind

  • Turns constructive (binary probe → momentum) on a daily close reclaiming ~$5.80–$6.00 with the reform cluster (CGC, MSOS components) breaking out together, or the hearing concluding with an explicit adult-use Schedule III recommendation.
  • Thesis breaks on a daily close below $4.50 (loss of the pre-hearing base), the hearing punting to litigation or excluding adult-use, or the CGC 2026-06-15 restatement/print cratering sector sentiment ahead of June 29.
  • The hemp-THC ban being repealed or indefinitely deferred would remove the gray-market-clearing tailwind and weaken the secondary bull leg.

Correlation Notes

  • High beta to the US cannabis-reform complex: trades with CGC and the MSO group (Trulieve, Curaleaf, Green Thumb) and the MSOS ETF; reform headlines move the whole basket together.
  • Idiosyncratic dampener: post-BrewDog, a large revenue slice tracks beverage-alcohol fundamentals, so TLRY carries less pure reform beta than the MSOs into the 2026-06-29 catalyst.
  • Hemp-THC ban is a cross-current within the theme bearish for hemp-derived-THC sellers, bullish for licensed cannabis by removing competition; the politics (effective ~2026-11-12 vs deferral bills) keep it unsettled.
  • Germany/EU exposure (+70% YoY international cannabis) provides a non-US-reform growth leg that can diverge from the US rescheduling tape.

Notes

  • EARNINGS BLACKOUT: TLRY Q4/FY2026 reports ~2026-07-29 after close (confirmed) no fresh entries within 3 trading days prior.
  • Canonical cannabis-reform VALUE TRAP: stock round-tripped $5→$23→$5; never average down, re-enter only on a fresh higher-low.
  • April 2026 partial rescheduling (FDA-approved + state-medical → Sched III) already landed 2026-04-23 and was SOLD; recreational still Schedule I until the June 29 hearing changes it.
  • BrewDog acquisition makes TLRY ~$1.2B annualized and increasingly a craft-beer company cannabis is only ~31% of revenue, diluting reform beta.
  • Germany/international cannabis +70% YoY is the only genuinely accelerating leg, independent of US reform.
  • Structure check: below 200-day SMA, ChartMill 0/10 a momentum entry needs a daily close back above ~$5.80–$6.00 first.
  • EARNINGS BLACKOUT: TLRY Q4/FY2026 reports ~late July 2026 (July 27–29 est.) after close no fresh entries within 3 trading days prior.
  • Canonical cannabis-reform value trap: stock round-tripped $5→$23→$5; never average down, re-enter only on a fresh higher-low.
  • April 2026 partial rescheduling (FDA-approved + state-medical → Sched III) landed 2026-04-23 and was sold; recreational stays Schedule I until the June 29 hearing changes it.
  • BrewDog acquisition makes TLRY ~$1.2B annualized and increasingly a craft-beer company cannabis is ~31% of revenue, diluting reform beta.
  • Structure check: below 200-day SMA, ChartMill 0/10 a momentum entry needs a daily close back above ~$5.80–6.00 first.
  • NEW hemp-THC crosscurrent: Congress recriminalized intoxicating hemp-derived THC (0.4mg/container cap, effective ~2026-11-12 unless H.R. 7024 defers to 2028); removes gray-market competition (bullish for licensed cannabis) but politically unsettled White House pushed Congress to preserve CBD 2026-06-05.
  • Peer read-through: CGC reports FY2026 2026-06-15 WITH a restatement of FY2024/FY2025 (non-cash warrant accounting error) watch sector sentiment two weeks before the hearing.
  • DEA hearing schedule: begins 2026-06-29 9am ET Arlington VA, recess 07-03, reconvene 07-06, concludes ≤07-15 with a recommendation (not a final rule).

Related · shared themes

ACB

Aurora Cannabis Inc.

Sentiment-beta proxy on the U.S. reschedule trade, but the wrong horse: a Canadian LP with no U.S. THC ops, lagging at its 52-wk low ($3.46) while MSOS rips +7.6% (Jun 4) into the Jun 29 DEA hearing. Jun 11 pre-open earnings is the nearer binary. Probe-only lottery ticket, not a momentum setup.

LOW

CGC

Canopy Growth Corporation

Cannabis Schedule III narrative is ACCELERATING federally (DEA adult-use rescheduling hearing 2026-06-29→07-15), but CGC is a diluted Canadian proxy at $1.04 near its 52-wk low, with a restatement-bundled 2026-06-15 print arriving first. LOW-conviction binary-event option on the wrong vehicle, not a momentum setup.

LOW